DC ChemicalsChemicals for Life Science
sales@dcchemicals.com

DC33636 · Updated 24 October 2026

DOTAP
Formulation & Performance

This edition organizes the previously reviewed, source-linked product record. It is not a new independent review of every paper or supporting file. Reported and calculated values retain their original labels.

Literature-reported formulation composition

ComponentReported molar ratioRole
DOTAP1Ionizable lipid
Cholesterol3Sterol
Reported ratio sum4Original ratio retained

Component molecular weights and calculated amounts

Composition retained from the cited study below. Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.

ComponentMolecular weightMolar partsNormalized mol%Amount (µmol)Weight (mg)
DOTAP25.00053.806737.5869
Cholesterol75.000161.420162.4131

Calculated total: 100.0000 mg lipid.

Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.

Not reported in the cited article
Not reported
10 mM PBS, pH 7.4
GFP-expressing mRNA
In vitro addition to complete cell-culture medium
1 microgram mRNA with 62.5 micromolar total lipid
SK-OV-3 human ovarian cancer cells, 100,000 cells per well
DOTAP and cholesterol were dissolved in 2 mL chloroform at 10 micromoles total lipid, rotary-evaporated to a thin film, hydrated with 1 mL 10 mM PBS using repeated 30-second sonication and 60-second vortex cycles, extruded ten times through 200 nm and then 100 nm membranes, and complexed with 1 microgram mRNA for 30 minutes at room temperature.

Literature-reported performance for the cited formulation

Literature-reported49.4 ± 2.12%DOTAP/cholesterol 1:3 molar ratio, non-PEGylated, 62.5 micromolar total lipid, 1 microgram GFP mRNA · 24 h · JetPRIME 38.06 ± 3.68%; p = 0.017PMC full text, Results: In Vitro mRNA Transfection; Fig.4
Literature-reportedComplete binding for every tested non-PEGylated DOTAP/cholesterol ratio and lipid concentration1 microgram mRNA; DOTAP/cholesterol ratios 2:1, 1:1, 1:2, 1:3 and 1:4; total lipid 31.25, 62.5 or 125 micromolarPMC full text, Results: Gel Retardation Assay; Fig.2a
Literature-reportedNo significant loss of transfection efficiency was reported through 60 days at 4 degrees CSelected non-PEGylated 1:3 formulation; compared over storage time · 0, 30 and 60 daysPMC full text, Stability Study; Fig.7
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetSun M, Dang UJ, Yuan Y, et al. Optimization of DOTAP/chol Cationic Lipid Nanoparticles for mRNA, pDNA, and Oligonucleotide Delivery. AAPS PharmSciTech. 2022;23:135. DOI: 10.1208/s12249-022-02294-w
Results are limited to the specified DOTAP/cholesterol lipoplex, preparation, cell line, cargo and exposure time.

Primary article